Ashutosh Tewari, MD
Urology · New York, NYNPI 1790873065
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (35.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Medtronic at 35.7% of the total. Reporting peaked in 2023 at $2,439 and has fallen 80.9% since, to $465 in 2025.
Across 45 payments — averaging $77.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Johnson & Johnson$1K
- Pfizer$181
- Myriad Genetic Laboratories, Inc.$125
- Sumitomo Pharma America, Inc.$111
- AbbVie$87
- plus $523 from 16 others
Across 212 payments — averaging $11,780 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$886K
- Blue Earth Diagnostics$656K
- Bayer$308K
- Merck$250K
- Dendreon Pharmaceuticals LLC$243K
- Gilead$85K
- plus $69K from 2 others
What the payments were for
- Consulting fees$1,09031%
- Travel & lodging$1,24936%
- Food & beverage$1,14433%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $1,243 |
| Johnson & Johnson | 5 | $1,212 |
| Pfizer | 3 | $181 |
| Myriad Genetic Laboratories, Inc. | 7 | $125 |
| Sumitomo Pharma America, Inc. | 4 | $111 |
| AbbVie | 4 | $87 |
| Bayer | 4 | $83 |
| Intuitive Surgical | 1 | $53 |
| Caris MPI, Inc. | 1 | $47 |
| Profound Medical Corp. | 1 | $46 |
| Verity Pharmaceuticals Inc. | 2 | $46 |
| Axogen | 1 | $40 |
| Urogen Pharma, Inc. | 1 | $32 |
| Ambu Inc. | 1 | $30 |
| Telix Pharmaceuticals | 1 | $28 |
| Coloplast | 1 | $27 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Procept Biorobotics Corporation | 1 | $19 |
| Blue Earth Diagnostics | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Hollister Incorporated | 1 | $14 |
| EDAP Technomed Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,483 in reported general payments places this provider in the 55th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 81 | $43,657 |
| MyrbetriqMirabegron | 37 | $25,843 |
| Mirabegron ErMirabegron | 17 | $7,380 |
| Tamsulosin Hcl | 322 | $3,793 |
| Solifenacin Succinate | 52 | $1,766 |
| Tadalafil | 22 | $1,231 |
| Finasteride | 54 | $669 |
| Dutasteride | 22 | $497 |
| Duloxetine Hcl | 38 | $279 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 146 | $254 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $244 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 36 | $192 |
| Ciprofloxacin Hcl | 52 | $179 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 29 | $76 |
| Cephalexin | 15 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $111 | $43,65781 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $25,84337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 952 urology providers in New York.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.